Logo image of DIAX

NUVEEN DOW 30 DYNAMIC OVERWR (DIAX) Stock Price, Quote, News and Overview

NYSE:DIAX - New York Stock Exchange, Inc. - US67075F1057 - Currency: USD

14.3  +0.03 (+0.21%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DIAX. DIAX was compared to 0 industry peers in the Unkown industry. While DIAX seems to be doing ok healthwise, there are quite some concerns on its profitability. DIAX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DIAX has reported negative net income.
In multiple years DIAX reported negative net income over the last 5 years.
DIAX had a negative operating cash flow in each of the past 5 years.
DIAX Yearly Net Income VS EBIT VS OCF VS FCFDIAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

Industry RankSector Rank
ROA -4.59%
ROE -4.64%
ROIC 0.97%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DIAX Yearly ROA, ROE, ROICDIAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15

1.3 Margins

DIAX's Profit Margin has been stable in the last couple of years.
DIAX's Operating Margin has declined in the last couple of years.
DIAX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 56.42%
PM (TTM) N/A
GM 58.6%
OM growth 3Y0.37%
OM growth 5Y-3.3%
PM growth 3Y-9.83%
PM growth 5Y-0.39%
GM growth 3Y-1.03%
GM growth 5Y-4.15%
DIAX Yearly Profit, Operating, Gross MarginsDIAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

More info and screens

5

2. Health

2.1 Basic Checks

DIAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DIAX Yearly Shares OutstandingDIAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
DIAX Yearly Total Debt VS Total AssetsDIAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

An Altman-Z score of 57.48 indicates that DIAX is not in any danger for bankruptcy at the moment.
DIAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 57.48
ROIC/WACCN/A
WACCN/A
DIAX Yearly LT Debt VS Equity VS FCFDIAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.3 Liquidity

DIAX has a Current Ratio of 0.04. This is a bad value and indicates that DIAX is not financially healthy enough and could expect problems in meeting its short term obligations.
DIAX has a Quick Ratio of 0.04. This is a bad value and indicates that DIAX is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
DIAX Yearly Current Assets VS Current LiabilitesDIAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

DIAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -129.76%.
The Earnings Per Share has been decreasing by -7.42% on average over the past years.
Looking at the last year, DIAX shows a small growth in Revenue. The Revenue has grown by 5.85% in the last year.
The Revenue has been decreasing by -7.07% on average over the past years.
EPS 1Y (TTM)-129.76%
EPS 3Y-12.76%
EPS 5Y-7.42%
EPS Q2Q%36.76%
Revenue 1Y (TTM)5.85%
Revenue growth 3Y-3.23%
Revenue growth 5Y-7.07%
Sales Q2Q%5.57%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DIAX Yearly Revenue VS EstimatesDIAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DIAX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DIAX Price Earnings VS Forward Price EarningsDIAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DIAX Per share dataDIAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 8.34%, DIAX is a good candidate for dividend investing.
DIAX's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 8.34%

5.2 History

DIAX has been paying a dividend for at least 10 years, so it has a reliable track record.
DIAX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years3
DIAX Yearly Dividends per shareDIAX Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
DIAX Yearly Income VS Free CF VS DividendDIAX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

More info and screens

NUVEEN DOW 30 DYNAMIC OVERWR

NYSE:DIAX (7/21/2025, 11:55:15 AM)

14.3

+0.03 (+0.21%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners36.74%
Inst Owner Change-2.52%
Ins OwnersN/A
Ins Owner Change0%
Market Cap520.09M
Analysts0
Price TargetN/A
Short Float %0.05%
Short Ratio0.28
Dividend
Industry RankSector Rank
Dividend Yield 8.34%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years1
Div Non Decr Years3
Ex-Date06-13 2025-06-13 (0.301)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.47
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.35
BVpS16.19
TBVpS16.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.59%
ROE -4.64%
ROCE 1.23%
ROIC 0.97%
ROICexc 0.97%
ROICexgc 0.97%
OM 56.42%
PM (TTM) N/A
GM 58.6%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y0.37%
OM growth 5Y-3.3%
PM growth 3Y-9.83%
PM growth 5Y-0.39%
GM growth 3Y-1.03%
GM growth 5Y-4.15%
F-ScoreN/A
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z 57.48
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.76%
EPS 3Y-12.76%
EPS 5Y-7.42%
EPS Q2Q%36.76%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.85%
Revenue growth 3Y-3.23%
Revenue growth 5Y-7.07%
Sales Q2Q%5.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.12%
EBIT growth 3Y-2.88%
EBIT growth 5Y-10.13%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A